Lumos Pharma Announces Clinical Updates
July 20, 2021 16:01 ET
|
Lumos Pharma, Inc.
OraGrowtH210 Trial in PGHD primary outcome 6-month data now anticipated in 2H2023; treatment period to be extended to 12 monthsOraGrowtH212 PK/PD Trial initiated in Q2 2021; treatment period to be...
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
June 28, 2021 08:00 ET
|
Lumos Pharma, Inc.
Single-Center Phase 2 Trial to Study the Pharmacokinetics/Pharmacodynamics (PK/PD) and Unique Pulsatile Mechanism of Action of LUM-201 at Two Dose Levels AUSTIN, Texas, June 28, 2021 (GLOBE...
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
May 19, 2021 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
May 13, 2021 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
May 05, 2021 16:01 ET
|
Lumos Pharma, Inc.
Newly released PK/PD data from prior study in PGHD support endogenous LUM-201 MOA and use of Predictive Enrichment Markers (PEMs) to identify patients likely to respond to LUM-201 Data presented...
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
April 28, 2021 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
April 27, 2021 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, April 27, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that new...
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
April 20, 2021 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, April 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced several changes...
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
April 14, 2021 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, April 14, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that it...
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
March 20, 2021 11:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, March 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the poster...